MastiTube

PROJECT NAME: MastiTube

COMPANY: Destina Genomica S.L.

COUNTRY: Spain

ORIGIN SECTOR: HEALTH

APPLICATION SECTOR: AGRIFOOD

Contact information

Juan Enrique Cruz Romera

juan@destinagenomics.com

MastiTube

Bovine Mastitis DestiNA Spin-Tube

Bovine mastitis is a major worldwide problem in the dairy industry, with significant economic costs for dairy farmers and milk processors. The average costs under Dutch circumstances of a case of clinical mastitis are estimated to be €277 and €168 for cows in early and late lactation respectively. Using the calculations of De Vos, C.J. and Dijkhuizen, A.A. (1998) “Economical aspects of udder health” (in Dutch). the yearly economic damage of clinical mastitis for Dutch farmers exceeds €100m, assuming a yearly incidence rate of 25% and 1.6 million dairy cows at risk each year. Dutch milk count for almost 10% of the total EU production milk.

Current milk testing involves culture and/or PCR to identify bacterial pathogens which is time consuming and expensive. We propose to apply the Bovine Mastitis DestiNA Spin-Tube, a novel medical multiplex diagnostic platform based on a direct detection of mastitis pathogen rRNA sequences, without the need for culture or PCR. Our test will revolutionise testing for mastitis offering a cost per test of 2€. The Bovine Mastitis Spin-Tube Project, developed from the DestiNA Spin-Tube for human parasite infections, will thus offer a rapid, accurate and low cost detection of bovine mastitis.

Further, it will increase investment being made by DestiNA Genomica S.L. in innovative R&D, extension from the biomedical field to the Agrofood sector, and internationalisation of Andalusian foreign trade with countries with significant dairy herds.

About the company

DestiNA Genomics Ltd (DGL) was founded in April 2010 by Hugh Ilyine, Juan J. Diaz-Mochon and Mark Bradley as a start-up from Edinburgh University, based on the research and validation of novel “dynamic chemistry” approaches for error free detection of nucleic acids and their mutations. The technology is unique and distinguishable from ALL existing enzymatic methods of nucleic acid analysis. DestiNA demonstrated its patented SMART Nucleobase technology worked 100% accurately in detecting mutations in blind testing of Cystic Fibrosis patient blood samples. In January 2011, DGL was formally spun-out with a worldwide, exclusive licence to the technology granted by the University.

DestiNA Genomics Ltd (DGL) was formed to commercialise a revolutionary chemical based system for detecting nucleic acids and single nucleotide polymorphisms (SNPs). In particular, DGL is focused on development of simpler, faster more accurate and cost effective products for PCR free detection of microRNAs, valuable as biomarkers for toxicology, illness and disease. DestiNA aims to become a leading manufacturer and supplier of custom chemical reagents for biomarker assays. Products in development include improved sample preparation and RNA stabilisation, refrigeration free handling, shipment and storage, as well as its library of patented SMART Nucleobases and custom probes.

In July 2012, DGL incorporated a Spanish subsidiary DestiNA Genomica S.L. (DGSL) with the goal to accelerate research and development of its technology in Spain with partners such as Master Diagnóstica. Support from the Technological Fund of ‘Invest in Spain’, has allowed DGSL to developed and integrate its patented SMART Nucleobase technology with Master Diagnóstica’s e-BRID System. DestiNA has 11 employees.

DGL has developed a range of strong collaborations with universities in the UK, Spain, Italy, Belgium and Greece,. and in particular the GENYO Institute at the University of Granada (Spain).

More information: https://sites.google.com/destinagenomics.com/home

Share this:

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close